BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petasis NA, Akritopoulou-Zanze I, Fokin VV, Bernasconi G, Keledjian R, Yang R, Uddin J, Nagulapalli KC, Serhan CN. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005;73:301-21. [PMID: 16098719 DOI: 10.1016/j.plefa.2005.05.020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Rainsford K. Anti-Inflammatory Drugs in the 21st Century. In: Harris RE, Bittman R, Dasgupta D, Engelhardt H, Flohe L, Herrmann H, Holzenburg A, Nasheuer H, Rottem S, Wyss M, Zwickl P, editors. Inflammation in the Pathogenesis of Chronic Diseases. Dordrecht: Springer Netherlands; 2007. pp. 3-27. [DOI: 10.1007/1-4020-5688-5_1] [Cited by in Crossref: 257] [Cited by in F6Publishing: 208] [Article Influence: 17.1] [Reference Citation Analysis]
2 Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011;111:5922-43. [PMID: 21766791 DOI: 10.1021/cr100396c] [Cited by in Crossref: 607] [Cited by in F6Publishing: 560] [Article Influence: 55.2] [Reference Citation Analysis]
3 Magdalon J, Vinolo MAR, Rodrigues HG, Paschoal VA, Torres RP, Mancini-filho J, Calder PC, Hatanaka E, Curi R. Oral Administration of Oleic or Linoleic Acids Modulates the Production of Inflammatory Mediators by Rat Macrophages. Lipids 2012;47:803-12. [DOI: 10.1007/s11745-012-3687-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
4 Corminboeuf O, Leroy X. FPR2/ALXR agonists and the resolution of inflammation. J Med Chem 2015;58:537-59. [PMID: 25365541 DOI: 10.1021/jm501051x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 10.1] [Reference Citation Analysis]
5 Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010;107:1170-84. [PMID: 21071715 DOI: 10.1161/CIRCRESAHA.110.223883] [Cited by in Crossref: 266] [Cited by in F6Publishing: 133] [Article Influence: 22.2] [Reference Citation Analysis]
6 Ríos JD, Hughes CK, Lally J, Wienandt N, Esquivel C, Serhan CN, Weitzel EK. Neuroprotectin D1 Attenuates Blast Overpressure Induced Reactive Microglial Cells in the Cochlea. Laryngoscope 2021;131:E2018-25. [PMID: 33427310 DOI: 10.1002/lary.29337] [Reference Citation Analysis]
7 Duffy CD, Guiry PJ. Recent advances in the chemistry and biology of stable synthetic Lipoxin analogues. Med Chem Commun 2010;1:249. [DOI: 10.1039/c0md00136h] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Fu T, Mohan M, Brennan EP, Woodman OL, Godson C, Kantharidis P, Ritchie RH, Qin CX. Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease. ACS Pharmacol Transl Sci 2020;3:43-55. [PMID: 32259087 DOI: 10.1021/acsptsci.9b00097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
9 Decker Y, McBean G, Godson C. Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am J Physiol Cell Physiol 2009;296:C1420-7. [PMID: 19357230 DOI: 10.1152/ajpcell.00380.2008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
10 Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, Brightling CE, Busse WW, Castro M, Dahlen B. Severe asthma in adults: what are the important questions. J Allergy Clin Immunol. 2007;119:1337-1348. [PMID: 17416409 DOI: 10.1016/j.jaci.2006.11.702] [Cited by in Crossref: 203] [Cited by in F6Publishing: 189] [Article Influence: 13.5] [Reference Citation Analysis]
11 Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008;153 Suppl 1:S200-S215. [PMID: 17965751 DOI: 10.1038/sj.bjp.0707489] [Cited by in Crossref: 217] [Cited by in F6Publishing: 235] [Article Influence: 14.5] [Reference Citation Analysis]
12 Planaguma A, Levy BD. Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling. Future Lipidol 2008;3:697-704. [PMID: 19293940 DOI: 10.2217/17460875.3.6.697] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Homann J, Suo J, Schmidt M, de Bruin N, Scholich K, Geisslinger G, Ferreirós N. In Vivo Availability of Pro-Resolving Lipid Mediators in Oxazolone Induced Dermal Inflammation in the Mouse. PLoS One 2015;10:e0143141. [PMID: 26599340 DOI: 10.1371/journal.pone.0143141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pommery N, Massingham R, Hénichart J. 5-Lipoxygenase inhibitors – patent and literature activity during 2001 – 2004. Expert Opinion on Therapeutic Patents 2005;16:13-26. [DOI: 10.1517/13543776.16.1.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Dabdoub MJ, Dabdoub VB, Baroni ACM, Barbosa SL. Four- and Eight-Carbon Homologation of Benzaldehyde by (1 Z ,3 Z )-Butyltelluro-1,3-Butadiene: Synthesis of Navenone B: Alarm Pheromone of the Mollusk Navanax inermis. Synthetic Communications 2012;42:942-50. [DOI: 10.1080/00397911.2010.528131] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Trojan E, Bryniarska N, Leśkiewicz M, Regulska M, Chamera K, Szuster-Głuszczak M, Leopoldo M, Lacivita E, Basta-Kaim A. The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology. Curr Neuropharmacol 2020;18:229-49. [PMID: 31629396 DOI: 10.2174/1570159X17666191019170244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
17 Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol 2012;189:1036-42. [PMID: 22711890 DOI: 10.4049/jimmunol.1103483] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
18 Leyva A, Blum FE, Hewitt PR, Ley SV. Functionalised butanediacetal-protected 1,2-diols as suitable partners for Pd-catalysed cross-coupling reactions. Tetrahedron 2008;64:2348-58. [DOI: 10.1016/j.tet.2008.01.010] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
19 Winkler JW, Uddin J, Serhan CN, Petasis NA. Stereocontrolled total synthesis of the potent anti-inflammatory and pro-resolving lipid mediator resolvin D3 and its aspirin-triggered 17R-epimer. Org Lett 2013;15:1424-7. [PMID: 23510485 DOI: 10.1021/ol400484u] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
20 Petasis NA, Keledjian R, Sun YP, Nagulapalli KC, Tjonahen E, Yang R, Serhan CN. Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg Med Chem Lett 2008;18:1382-7. [PMID: 18249111 DOI: 10.1016/j.bmcl.2008.01.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
21 Hansen TV, Vik A, Serhan CN. The Protectin Family of Specialized Pro-resolving Mediators: Potent Immunoresolvents Enabling Innovative Approaches to Target Obesity and Diabetes. Front Pharmacol 2018;9:1582. [PMID: 30705632 DOI: 10.3389/fphar.2018.01582] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
22 Dobson EP, Barrow CJ, Adcock JL. Solvent-induced 7R-dioxygenase activity of soybean 15-lipoxygenase-1 in the formation of omega-3 DPA-derived resolvin analogs. Journal of Molecular Catalysis B: Enzymatic 2014;108:96-102. [DOI: 10.1016/j.molcatb.2014.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
23 Higgins G, Ringholz F, Buchanan P, McNally P, Urbach V. Physiological impact of abnormal lipoxin A₄ production on cystic fibrosis airway epithelium and therapeutic potential. Biomed Res Int 2015;2015:781087. [PMID: 25866809 DOI: 10.1155/2015/781087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lin F, Yu X, Zhang X, Guo Y, Huang Y, Zhou J, Zeng P, Ye D, Huang Y. A synthetic analog of lipoxin A4 partially alleviates dexamethasone-induced fetal growth restriction in rats. Placenta 2013;34:941-8. [DOI: 10.1016/j.placenta.2013.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
25 Oger C, Balas L, Durand T, Galano JM. Are alkyne reductions chemo-, regio-, and stereoselective enough to provide pure (Z)-olefins in polyfunctionalized bioactive molecules? Chem Rev 2013;113:1313-50. [PMID: 23194255 DOI: 10.1021/cr3001753] [Cited by in Crossref: 214] [Cited by in F6Publishing: 155] [Article Influence: 21.4] [Reference Citation Analysis]
26 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
27 Börgeson E, Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol 2012;3:318. [PMID: 23087692 DOI: 10.3389/fimmu.2012.00318] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
28 Chen Q, Zhou W, Pu D, Li Z, Huang Q, Chen Q. The inhibitory effect of 15-R-LXA4 on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol 2009;145:200-4. [PMID: 19523744 DOI: 10.1016/j.ejogrb.2009.05.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
29 Brightling CE, Gupta S, Gonem S, Siddiqui S. Lung damage and airway remodelling in severe asthma. Clin Exp Allergy 2012;42:638-49. [PMID: 22192725 DOI: 10.1111/j.1365-2222.2011.03917.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
30 Chen QF, Hao H, Kuang XD, Hu QD, Huang YH, Zhou XY. BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system. Prostaglandins Other Lipid Mediat 2019;140:9-17. [PMID: 30412790 DOI: 10.1016/j.prostaglandins.2018.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
31 Kowal-Bielecka O, Kowal K, Distler O, Gay S. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. Nat Clin Pract Rheumatol 2007;3:43-51. [PMID: 17203008 DOI: 10.1038/ncprheum0375] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
32 Bürli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, Adlam M, Plant MH, Wong M, McElvain M, Regal K, Viswanadhan VN, Tagari P, Hungate R. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett 2006;16:3713-8. [PMID: 16697190 DOI: 10.1016/j.bmcl.2006.04.068] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 5.3] [Reference Citation Analysis]
33 Haworth O, Levy BD. Endogenous lipid mediators in the resolution of airway inflammation. Eur Respir J 2007;30:980-92. [PMID: 17978156 DOI: 10.1183/09031936.00005807] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
34 Barth C, Guiry PJ. The medicinal chemistry of stable synthetic leukotriene B 3 and B 4 analogues. Future Medicinal Chemistry 2012;4:1007-14. [DOI: 10.4155/fmc.12.53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, Parkinson JF. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007;21:3877-84. [PMID: 17625069 DOI: 10.1096/fj.07-8653com] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 5.3] [Reference Citation Analysis]
36 Caligiuri SP, Aukema HM, Ravandi A, Pierce GN. Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption. Exp Gerontol 2014;59:51-7. [PMID: 24747581 DOI: 10.1016/j.exger.2014.04.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
37 Vik A, Dalli J, Hansen TV. Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid. Bioorg Med Chem Lett 2017;27:2259-66. [PMID: 28408222 DOI: 10.1016/j.bmcl.2017.03.079] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
38 Patel N, Gonsalves CS, Yang M, Malik P, Kalra VK. Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood 2009;113:1129-38. [PMID: 18945963 DOI: 10.1182/blood-2008-07-169821] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
39 Qu L, Caterina MJ. Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37. J Clin Invest 2018;128:3246-9. [PMID: 30010628 DOI: 10.1172/JCI122203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
40 Ismael A, Zeeshan M, Hansen JH. Synthesis of aromatic lactone analogues of Lipoxin A4. BMC Res Notes 2022;15:30. [PMID: 35139886 DOI: 10.1186/s13104-022-05917-4] [Reference Citation Analysis]
41 Dunn HC, Ager RR, Baglietto-Vargas D, Cheng D, Kitazawa M, Cribbs DH, Medeiros R. Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model. J Alzheimers Dis 2015;43:893-903. [PMID: 25125468 DOI: 10.3233/JAD-141335] [Cited by in Crossref: 53] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]